KRAS and familial pancreatic carcinoma: In the current work, we describe compounds that choose between the KRAS promoter G4near and G4mid structures, using the MYC promoter G4 as a comparative known entity, discuss the synthesis and activity of novel indoloquinolone compounds, and highlight the potential of these compounds in combination with chemotherapy in pancreatic cancer cell lines.